Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide in stable heart failure with reduced ejection fraction
NL-OMON45900Phase 2Active, not recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- Aug 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elamipretide in heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF) and Cardiomyopathies (3 arms), sponsored by Stealth BioTherapeutics. Primary endpoint: Change from baseline in left ventricular end systolic volume. Started Aug 2016; status: active, not recruiting.
02
Drugs
elamipretide
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)Cardiomyopathies
Beyond the preview
Go deeper on NL-OMON45900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45900.